Skip to main content

Table 3 Results of incremental cost-effectiveness ratios (ICER) in base case and probability sensitivity analysis

From: Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Short-term (at end of 12-months) NRT + counselling NRT + counselling
+ genetic test
Difference  
Cost for 1000 persons in each arm $802,100 $1,158,000 $355,600  
Number of quitters @ 12 months 60 110 50  
ICER - per quitter @ 12 months - - $7,112  
Long-term (at end of 35 years)     
Mean cost per person $6,600 $6,900 $300  
QALYs gained per person 14.288 14.298 0.0109  
ICER - QALYs gained per person - - $27,5721  
Monte Carlo simulated ICERs Incremental costs2 Incremental
QALYs
ICERs (QALYs) (95% CIs)
Base case ICER $299.46 0.0109 $34,6873 ($12,483, $87,734)
Initial cohort aged 30 years $341.69 0.0032 $133,409 ($53,502, $361,376)
Initial cohort aged 60 years $275.66 0.0126 $27,601 ($8,783, $73,948)
Men only (aged 50 years) $286.23 0.0130 $27,182 ($9,200, $70,783)
Women only (aged 50 years) $334.53 0.0049 $46,408 ($17,199, $118,383)
  1. 1. ICER of simple average results - single mean cost and effect differences.
  2. 2. Statistically significantly different mean costs and effects between groups (p < 0.001)
  3. 3. Average ICER of 1,000 simulations, not ICER of average results.